This past year a tremendous amount of new "practice-changing" data affecting how you treat, manage and care for your hematology patients has been published. For your lymphoma, myeloma and leukemia patients this symposium will help you apply the new first-line and maintenance therapy data as well as the best practices for your refractory and relapsed patients.

Taught by the expert hematology academics who are highly effective and engaging teachers, this Patient Case-Based program is the ONE symposium on hematologic malignancies that you should attend in 2011. It also provides the important highlights and data from the December 2010 ASH Symposium. So if there is only one hematology CME symposium that you should attend in 2011, please join us on February 5, 2011 in Tampa, FL. This is the second year of this very special symposium. It promises to continue to attract a full room of hematologists and allied health care professionals like you who will leave the symposium with the expert knowledge and competence needed to improve outcomes for patients with hematologic malignancies.

Register now for a guaranteed symposium seat, discounted tuition, hotel room rates and airline fares. Like last year, attendance will reach its maximum. Don't miss this opportunity.

Interactive patient cases are included in all presentations


The primary objective of the Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Hematologic Malignancies: CASE-BASED LEARNING is to help you treat your hematology patients with the optimal personalized approaches in order to improve patient outcomes and minimize drug-induced toxicities. This CME activity is especially designed to review practice-changing or “game-changing” clinical and scientific data on hematologic malignancies presented at the 2010 annual ASCO meeting, and at other important hematology meetings in 2010, including the June 2010 annual EHA meeting in Barcelona, the October 2010 ESMO meeting in Milan, and most recently at the December 2010 ASH Symposium on Orlando.

This symposium is "case-based" learning. The instructional design is one that is very highly interactive between the learners and the faculty. Each didactic presentation begins with a patient case study and the faculty uses the Audience Response System (ARS) for engaging you, the learner, throughout the program. This approach has been so successful that it is used for all of our live symposia to further facilitate learning. In addition, each of the symposium’s sessions will include one additional, dedicated, interactive clinical case study session for additional interaction between you and the faculty. And each of the three symposium sessions will conclude with a Q & A period for you with the faculty.

Registered symposium attendees may submit their own hematology patient cases until January 27, 2011 for review by the expert faculty during the February 5, 2011 symposium. Please submit your cases to steve.madison@olccme.com. Thank you.

The following major educational needs for your practices have been identified for review in this February 5, 2011 symposium.

• New data on the combination of rituximab plus bendamustine, or rituximab plus lenalidomide for Non-Hodgkin's Lymphoma needs to be reviewed.
• The new standard of care for follicular lymphoma is to use a maintenance therapy strategy based upon the PRIMA clinical study results and not to use observation for managing these patients.
• For patients with aggressive, relapsed, B-cell lymphoma the data from the VERTICAL and other published trials showing how to achieve better outcomes needs to be reviewed.
• For Hodgkin's Disease patients data regarding therapy with brentuximab has recently published clinical data showing that this strategy improves patient outcomes. This needs to be addressed.
• Data needs to be reviewed regarding adding a rituximab-targeted strategy to traditional chemotherapy for newly diagnosed patients with CLL that has demonstrated improved outcomes through both an overall survival and a progression-free survival advantage.
• For refractory CLL patients data needs to be reviewed to help improve outcomes when using either single-agent alemtuzumab or bendamustine, or other combinations the combinations of rituximab plus lenalidomide, or alemtuzumab plus fludarabine, and the use of single-agent lenalidomide or single-agent ofatumumab as additional options for CLL in the second-line or refractory setting.
• Cutaneous T-cell Lymphoma data to improve patient outcomes needs to be reviewed from the 2010 ASH and ASCO meetings.
• Peripheral T-cell Lymphoma data using pralatrexate, or bortezomib or forodesine to improve patient outcomes needs to be reviewed from the 2010 ASH and ASCO meetings needs to be reviewed.
• A new CML patient-management algorithm is evolving and is needed for both initial and refractory CML because there are now three drugs that are FDA-approved for CML, imatinib, nilotinib and dasatinib.
• How and when to perform mutation testing and/or using this information optimally in treatment planning and decision-making of CML patients needs to be reviewed.
• Data affecting outcomes with Acute Myelogenous Leukemia needs to be reviewed using the following drugs: lenalidomide, decitabine, azacitadine, vorinostat and midostaurin.
• For patients with Myelodysplastic Syndromes the newest efficacy data with lenalidomide plus HDAC inhibition, and with other strategies for this malignancy also needs to be reviewed.
• For patients with acute promyelocytic leukemia the phase II efficacy data with blinatumomab and the new data with arsenic trioxide as consolidation therapy may become a new standard for improving outcomes in APL. This needs to be reviewed.
• The significant efficacy data with the use of lenalidomide maintenance therapy for multiple myeloma patients needs a thorough review and update.
• The efficacy data with proteasome inhibition combined with either bortezomib or carfilzomib, and, lowered neuropathy with carfilzomib needs to be reviewed for multiple myeloma patients.
• The benefits of using panobinostat, lenalidomide or vorinostat along with bortezomib, and also perifosine experimentally, can improve MM patient outcomes. This needs a review.
• A review and update on the efficacy data is needed regarding zolendronic acid as an agent with a direct anti-tumor effect on multiple myeloma patients.